Overview Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the first FDA conditionally approved medication specifically developed to manage feline hypertrophic cardiomyopathy (HCM). Formulated for oral use in cats, Felycin™-CA1 contains sirolimus, which helps regulate pathways involved in abnormal heart muscle thickening. This prescription medication offers a new approach to feline cardiac care, improving treatment consistency and compliance.

  • First FDA conditionally approved treatment for feline HCM
  • Delayed-release tablets formulated for cats
  • Contains sirolimus to target heart muscle abnormalities
  • Oral administration supports at-home use
  • Designed to improve quality of life in cats with hypertrophic cardiomyopathy